Swing Trade Stock Picks
Home › Forums › Stocks › Swing Trading › Swing Trade Stock Picks
Tagged: Equities, Investing, Investments, Stock Market, Stock Picks, Stock Trading, Stocks, Swing Trade, Swing Trades, Swing Trading, Trade, Trade Stocks, Trading
- This topic has 144 replies, 2 voices, and was last updated 3 years, 3 months ago by
Michael DeVries.
-
AuthorPosts
-
November 19, 2017 at 9:43 am #2866
Michael DeVries
KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 11/20/2017 – 11/24/2017:
1) RWLK – Rewalk Robotics Ltd
a. Buy at < ~ $1.05
b. Sell at >~ $3.202) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.003) SGYP – Synergy Pharmaceuticals Inc
a. Buy at < ~ $1.68
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 3 – A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma; 20171201; 20211231; https://ClinicalTrials.gov/show/NCT02409186
2. Phase 1 – ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer; 20180101; 20190131; https://ClinicalTrials.gov/show/NCT02632071
3. NA – Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT02770651
4. NA – Xience Versus Synergy in Left Main PCI; 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02303717
5. Phase 3 data from first and second trials met primary endpoints – December 9 and 22, 2016. PDUFA date January 24, 2018. – Trulance (plecanatide) – Constipation-predominant irritable bowel syndrome (IBS-C) – PDUFA; 20180124; 20180124; http://ir.synergypharma.com/press-releases/detail/1850
6. NA – Ulcerative Colitis Relapse Prevention by Prebiotics; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT02865707
7. Phase 4 – Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT; 20180501; 20190501; https://ClinicalTrials.gov/show/NCT03112707
8. NA – Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy; 20180401; 20181130; https://ClinicalTrials.gov/show/NCT02594501
9. Phase 2 – Proteasome Inhibition in Acute Promyelocytic Leukemia; 20180501; 20180531; https://ClinicalTrials.gov/show/NCT01950611
10. Phase 1 – Cancer Stem Cell High-Throughput Drug Screening Study; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT02654964
11. Phase 4 – Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome; 20151001; 20191031; https://ClinicalTrials.gov/show/NCT02049229
12. NA – Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT); 20160824; 20190831; https://ClinicalTrials.gov/show/NCT01674803
13. Phase 3 – The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s); 20140901; 20180831; https://ClinicalTrials.gov/show/NCT01665053
14. NA – The OCT SORT-OUT VIII Study; 20150401; 20251231; https://ClinicalTrials.gov/show/NCT02253108
15. Phase 1Phase 2 – Daratumumab in Combination With ATRA; 20170501; 20180531; https://ClinicalTrials.gov/show/NCT02751255
16. NA – Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment; 20170701; 20190228; https://ClinicalTrials.gov/show/NCT02727582
17. Phase 2 – Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma; 20171001; 20210430; https://ClinicalTrials.gov/show/NCT02437812
18. Phase 4 – Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.; 20170501; 20180630; https://ClinicalTrials.gov/show/NCT02099617
19. Phase 4 – Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction; 20170701; 20180731; https://ClinicalTrials.gov/show/NCT02890589
20. Phase 4 – Optimization of Antiretroviral Therapy; 20180601; 20181231; https://ClinicalTrials.gov/show/NCT02935075
21. Phase 1 – Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients; 20190701; 20190701; https://ClinicalTrials.gov/show/NCT02152943
22. Phase 1 – Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance; 20190901; 20190930; https://ClinicalTrials.gov/show/NCT01197170
23. Phase 1Phase 2 – Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients; 20190501; 20190531; https://ClinicalTrials.gov/show/NCT02906800
24. NA – MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial; 20190601; 20191231; https://ClinicalTrials.gov/show/NCT03135275
25. Phase 4 – DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT03208907
26. Phase 3 – Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry; 20210630; 20211230; https://ClinicalTrials.gov/show/NCT03048825
27. NA – Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice; 20251201; 20251231; https://ClinicalTrials.gov/show/NCT01186133
28. Phase 1 – Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor; 20200831; 20240831; https://ClinicalTrials.gov/show/NCT03239145
29. NA – IRIS-Synergy Cohort in the IRIS-DES Registry; 20201201; 20250630; https://ClinicalTrials.gov/show/NCT02720419
30. Phase 4 – EVOLVE Short DAPT Study; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02605447
31. Phase 2 – An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT03120520
32. Phase 2 – Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY); 20180901; 20181031; https://ClinicalTrials.gov/show/NCT03018340
33. Phase 1Phase 2 – MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas; 20180630; 20191231; https://ClinicalTrials.gov/show/NCT02311582
34. Phase 1 – Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00708448
35. Phase 2 – CyBeR Association in Relapsed/Refractory DLBCL; 20181101; 20181231; https://ClinicalTrials.gov/show/NCT02758925
36. Early Phase 1 – Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia; 20190101; 20210131; https://ClinicalTrials.gov/show/NCT02621944
37. Phase 1 – A Study of APG-1252 in Patients With SCLC or Other Solid Tumors; 20190212; 20190212; https://ClinicalTrials.gov/show/NCT03080311
38. Phase 1 – Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma; 20181117; 20191117; https://ClinicalTrials.gov/show/NCT03233152
39. Phase 2Phase 3 – Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT021117984) ABIL – Ability Inc
a. Buy at < ~ $0.50
b. Sell at >~ $1.005) GNCA – Genocea Biosciences Inc
a. Buy at < ~ $1.03
b. Sell at >~ $2.00
c. Catalysts:
1. Q4 2017 Genocea Biosciences Inc Earnings Release (Estimated); 20180214; 20180214; https://www.google.com/finance?q=GNCA
2. Phase 2 – Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection; 20180630; 20180630; https://ClinicalTrials.gov/show/NCT03146403
3. NA – Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT029102846) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20171231; 20171231; http://investor.onconova.com/releasedetail.cfm?ReleaseID=1037302
3. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
4. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm
5. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
6. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
7. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
9. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
10. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT021687257) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx8) MBOT – Microbot Medical Inc
a. Buy at < ~ $1.00
b. Sell at >~ $1.509) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT0274086810) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.2011) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $0.80
b. Sell at >~ $1.05
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. Q2 2018 Oasmia Pharmaceutical AB Earnings Release (Estimated); 20171130; 20171130; https://www.google.com/finance?q=OASMWhat do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 11/20/2017 – 11/24/2017, and Why?
November 24, 2017 at 9:25 am #2885KeymasterBullish Stocks currently Trading Below Cash (TBC) as of 11/23/2017 include:
- $AVIR – Aviragen Therapeutics Inc :
- Cash/sh = $0.99
- $EGLT – Egalet Corp :
- Cash/sh = $1.95
- $OPHT – Ophthotech Corp :
- Cash/sh = $5.46
- $ROKA – Sorrento Tech Inc :
- Cash/sh = $3.18
- $VVUS – VIVUS, Inc. :
- Cash/sh = $2.23
Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?
November 24, 2017 at 9:35 am #2886Keymaster#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 11/23/2017 include:
- $HEB – Hemispherx BioPharma, Inc :
- Book/sh = $0.51
- $NVGN – Novogen Limited (ADR) :
- Book/sh = $21.56
- $ROKA – Sorrento Tech Inc :
- Book/sh = $5.93
- $ROSG – Rosetta Genomics Ltd. (USA) :
- Book/sh = $2.40
Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?
December 3, 2017 at 9:49 am #2922KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/04/2017 – 12/08/2017:
1) CRIS – Curis, Inc.
a. Buy at < ~ $0.79
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2 – Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02674750
2. Phase 1 – Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT01742988
3. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
4. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
5. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777
6. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT028128752) RWLK – Rewalk Robotics Ltd
a. Buy at < ~ $1.05
b. Sell at >~ $3.203) ABIL – Ability Inc
a. Buy at < ~ $0.44
b. Sell at >~ $1.004) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.005) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20171231; 20171231; http://investor.onconova.com/releasedetail.cfm?ReleaseID=1037302
3. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
4. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm
5. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
6. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
7. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
9. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
10. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT021687256) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx7) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT027408688) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.209) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $0.80
b. Sell at >~ $1.05
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 12/04/2017 – 12/08/2017, and Why?
December 10, 2017 at 12:12 pm #2952KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/11/2017 – 12/15/2017:
1) CRIS – Curis, Inc.
a. Buy at < ~ $0.79
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2 – Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02674750
2. Phase 1 – Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT01742988
3. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
4. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
5. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777
6. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT028128752) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.003) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx4) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT027408685) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.206) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 12/11/2017 – 12/15/2017, and Why?
December 10, 2017 at 1:03 pm #2953KeymasterBullish Stocks currently Trading Below Cash (TBC) as of 12/08/2017 include:
- $AVIR – Aviragen Therapeutics Inc :
- Cash/sh = $0.99
- $EGLT – Egalet Corp :
- Cash/sh = $1.95
- $FCSC – Fibrocell Science Inc :
- Cash/sh = $1.35
- $OPHT – Ophthotech Corp :
- Cash/sh = $5.46
- $ROKA – Sorrento Tech Inc :
- Cash/sh = $3.18
- $VVUS – VIVUS, Inc. :
- Cash/sh = $2.23
Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?
December 17, 2017 at 9:18 am #2988KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/18/2017 – 12/22/2017:
1) CRIS – Curis, Inc.
a. Buy at < ~ $0.76
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2 – Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02674750
2. Phase 1 – Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT01742988
3. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
4. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
5. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777
6. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT028128752) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx3) MBOT – Microbot Medical Inc
a. Buy at < ~ $1.00
b. Sell at >~ $1.504) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT027408685) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 12/18/2017 - 12/22/2017, and Why?
December 25, 2017 at 8:57 am #3015KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/25/2017 – 12/29/2017:
1) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx2) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $0.90
b. Sell at >~ $1.38
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-093) MBOT – Microbot Medical Inc
a. Buy at < ~ $1.00
b. Sell at >~ $1.504) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 12/25/2017 - 12/29/2017, and Why?
January 7, 2018 at 10:11 am #3054KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 01/08/2018 – 01/12/2018:
1) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $0.80
b. Sell at >~ $1.382) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx3) OVAS – OvaScience Inc – Trading Below Cash
a. Buy at < ~ $1.25
b. Sell at >~ $1.56
c. Catalysts:
1. OvaPrime study – reintroductions completed by the end of H1 2018; 20180101; 20180630; https://seekingalpha.com/news/3273112-ovascience-completes-enrollment-ovaprime-study
2. OvaScience to Present at the 36th Annual J.P. Morgan Healthcare Conference; 20180111; 20180111; https://finance.yahoo.com/news/ovascience-present-36th-annual-j-120000121.html
3. NA – Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure; 20220601; 20220630; https://ClinicalTrials.gov/show/NCT03021915What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 01/08/2018 – 01/12/2018, and Why?
January 7, 2018 at 12:24 pm #3056KeymasterBullish Stocks currently Trading Below Cash (TBC) as of 01/05/2018 include:
- $AVIR – Aviragen Therapeutics, Inc. :
- Cash/sh = $0.86
- $FCSC – Fibrocell Science Inc :
- Cash/sh = $1.35
- $OPHT – Ophthotech Corp :
- Cash/sh = $5.46
- $VVUS – VIVUS, Inc. :
- Cash/sh = $2.23
Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?
January 7, 2018 at 12:29 pm #3057Keymaster#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 01/05/2018 include:
- $NFEC – NF Energy Saving Corporation :
- Book/sh = $3.83
- $PERI – Perion Network Ltd :
- Book/sh = $2.21
- $ROSG – Rosetta Genomics Ltd. (USA) :
- Book/sh = $2.40
Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?
January 14, 2018 at 10:56 am #3074KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 01/15/2018 – 01/19/2018:
1) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $0.80
b. Sell at >~ $1.382) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx3) IMDZ – Immune Design Corp
a. Buy at < ~ $3.50
b. Sell at >~ $5.30
c. Catalysts:
1. Phase 1 – Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers; 20180430; 20190430; https://ClinicalTrials.gov/show/NCT02642809
2. Phase 1 – Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT02818023
3. Phase 1Phase 2 – Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkins Lymphoma; 20171201; 20180331; https://ClinicalTrials.gov/show/NCT02501473
4. Phase 1 – Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1; 20171231; 20200811; https://ClinicalTrials.gov/show/NCT02122861
5. Phase 1 – Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200); 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02043665
6. Phase 1Phase 2 – Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer; 20190801; 20200831; https://ClinicalTrials.gov/show/NCT02963610
7. Phase 2 – Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer; 20180901; 20190930; https://ClinicalTrials.gov/show/NCT02981303
8. Phase 2 – Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma; 20190101; 20190630; https://ClinicalTrials.gov/show/NCT02736266What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 01/15/2018 – 01/19/2018, and Why?
February 11, 2018 at 10:06 am #3140Keymaster#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 02/09/2018 include:
- $CECE – CECO Environmental Corp. :
- Book/sh = $5.17
- $JAGX – Jaguar Health, Inc. :
- Book/sh = $0.57
- $KZIA – Kazia Therapeutics :
- Book/sh = $21.56
- $NFEC – NF Energy Saving Corporation :
- Book/sh = $3.83
- $OVAS – OvaScience Inc :
- Book/sh = $2.03
- $ROSG – Rosetta Genomics Ltd. (USA) :
- Book/sh = $2.40
- $VICL – Vical Incorporated :
- Book/sh = $3.29
Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?
February 11, 2018 at 11:48 am #3144KeymasterBullish Stocks currently Trading Below Cash (TBC) as of 02/09/2018 include:
- $AVIR – Aviragen Therapeutics, Inc. :
- Cash/sh = $0.86
- $EGLT – Egalet Corporation :
- Cash/sh = $2.21
- $OPHT – Ophthotech Corp :
- Cash/sh = $5.46
- $OVAS – OvaScience Inc :
- Cash/sh = $2.08
- $VICL – Vical Incorporated :
- Cash/sh = $2.68
- $VVUS – VIVUS, Inc. :
- Cash/sh = $2.23
Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?
February 18, 2018 at 11:08 am #3164KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 02/19/2018 – 02/23/2018:
1) TTPH – Tetraphase Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $7.95
c. Catalysts:
1. Phase 1 – A Phase 1 TP-271 Oral PK Single Ascending Dose Study; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT03024034
2. Phase 1 – A Phase 1 Safety and PK Study of IV TP-271; 20180331; 20180430; https://ClinicalTrials.gov/show/NCT03234738
3. Phase 3 – Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT030325102) TWMC – Trans World Entertainment Corporation
a. Buy at < ~ $1.50
b. Sell at >~ $3.103) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.96
b. Sell at >~ $1.53What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 02/19/2018 – 02/23/2018, and Why?
March 4, 2018 at 10:25 am #3197KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/05/2018 – 03/09/2018:
1) TTPH – Tetraphase Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.05
b. Sell at >~ $7.95
c. Catalysts:
1. Phase 1 – A Phase 1 TP-271 Oral PK Single Ascending Dose Study; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT03024034
2. Phase 1 – A Phase 1 Safety and PK Study of IV TP-271; 20180331; 20180430; https://ClinicalTrials.gov/show/NCT03234738
3. Phase 3 – Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT030325102) TWMC – Trans World Entertainment Corporation
a. Buy at < ~ $1.50
b. Sell at >~ $3.103) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.96
b. Sell at >~ $1.534) CYCC – Cyclacel Pharmaceuticals, Inc. – Trading Below Cash
a. Buy at < ~ $1.47
b. Sell at >~ $2.15
c. Catalysts:
1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
3. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT012534605) AST – Asterias Biotherapeutics, Inc.
a. Buy at < ~ $1.95
b. Sell at >~ $2.30
c. Catalysts:
1. Phase 1/2 six-month top-line data due June 2018 with 12-month data due December 2018. 6-month data from Cohort 3 (AIS-A 20 million-cell cohort) and Cohort 4 (AIS-B 10 million-cell cohort) due February 2018, and the 12-month data from Cohorts 3 and 4 in August 2018. – AST-OPC1 SCiSTAR – Cervical spinal cord injury – Phase 1/2; 20180801; 20180831; https://finance.yahoo.com/news/asterias-biotherapeutics-reports-milestone-targets-125200132.html
2. Phase 1Phase 2 – Dose Escalation Study of AST-OPC1 in Spinal Cord Injury; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02302157
3. Phase 1/2 trial to be initiated 1H 2018 with initial safety and immunogenicity readouts due 2H 2018. – AST-VAC2 – Non-small cell lung cancer (NSCLC) – Phase 1/2; 20181231; 20181231; http://asteriasbiotherapeutics.com/inv_news_releases_text.php?releaseid=2324856&date=January+04%2C+2018&title=Asterias+Biotherapeutics+Reports+Milestone+Targets+for+2018What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/05/2018 - 03/09/2018, and Why?
March 18, 2018 at 8:50 am #3214KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/19/2018 – 03/23/2018:
1) GSAT – Globalstar, Inc.
a. Buy at < ~ $0.70
b. Sell at >~ $2.592) TWMC – Trans World Entertainment Corporation
a. Buy at < ~ $1.50
b. Sell at >~ $3.103) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.96
b. Sell at >~ $1.534) CYCC – Cyclacel Pharmaceuticals, Inc. – Trading Below Cash
a. Buy at < ~ $1.47
b. Sell at >~ $2.15
c. Catalysts:
1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
3. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/19/2018 - 03/23/2018, and Why?
March 25, 2018 at 9:47 am #3224KeymasterBullish Stocks currently Trading Below Cash (TBC) as of 03/23/2018 include:
- $CYCC – Cyclacel Pharmaceuticals, Inc. :
- Cash/sh = $2.16
- $EGLT – Egalet Corporation :
- Cash/sh = $2.31
- $OPHT – Ophthotech Corporation :
- Cash/sh = $4.90
- $OVAS – OvaScience, Inc. :
- Cash/sh = $2.22
- $VICL – Vical Incorporated :
- Cash/sh = $2.67
- $VVUS – VIVUS, Inc. :
- Cash/sh = $2.23
Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?
March 25, 2018 at 9:53 am #3225Keymaster#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 03/23/2018 include:
- $CECE – CECO Environmental Corp. :
- Book/sh = $5.17
- $CYCC – Cyclacel Pharmaceuticals, Inc. :
- Book/sh = $2.39
- $DCAR – DropCar, Inc. :
- Book/sh = $3.01
- $OVAS – OvaScience, Inc. :
- Book/sh = $2.03
- $ROSG – Rosetta Genomics Ltd. :
- Book/sh = $0.43
- $VICL – Vical Incorporated :
- Book/sh = $3.29
Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?
April 1, 2018 at 8:57 am #3240KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/02/2018 – 04/06/2018:
1) SEED – Origin Agritech Limited
a. Buy at < ~ $0.74
b. Sell at >~ $1.502) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.533) TTNP – Titan Pharmaceuticals, Inc.
a. Buy at < ~ $0.94
b. Sell at >~ $1.40
c. Catalysts:
1. Phase 1/2 treatment has commenced – noted October 11, 2017. Data from first patient cohort due 1H 2018. – Ropinirole implant – Parkinson’s disease – Phase 1/2; 20180630; 20180630; https://ir.titanpharm.com/all-sec-filings/content/0001144204-18-001164/tv482843_ex99-1.htm
2. Phase 2 – Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome; 20180301; 20190331; https://ClinicalTrials.gov/show/NCT02867878
3. Phase 1Phase 2 – Relative Bioavailability Study of Ropinirole Implants in Parkinsons Patients on L-Dopa Switched From Oral Ropinirole; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT03250117
4. Phase 3 – A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC; 20201104; 20220713; https://ClinicalTrials.gov/show/NCT02489318
5. Phase 2 – Immunological and Regenerative Implications of Corrosion of Dental Materials in Children and Adolescents; 20181231; 20191230; https://ClinicalTrials.gov/show/NCT03334461What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/02/2018 – 04/06/2018, and Why?
April 8, 2018 at 9:28 am #3252KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/09/2018 – 04/13/2018:
1) TIK – Tel-Instrument Electronics Corp.
a. Buy at < ~ $2.06
b. Sell at >~ $3.852) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.533) TTNP – Titan Pharmaceuticals, Inc.
a. Buy at < ~ $0.94
b. Sell at >~ $1.40
c. Catalysts:
1. Phase 1/2 treatment has commenced – noted October 11, 2017. Data from first patient cohort due 1H 2018. – Ropinirole implant – Parkinson’s disease – Phase 1/2; 20180630; 20180630; https://ir.titanpharm.com/all-sec-filings/content/0001144204-18-001164/tv482843_ex99-1.htm
2. Phase 2 – Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome; 20180301; 20190331; https://ClinicalTrials.gov/show/NCT02867878
3. Phase 1Phase 2 – Relative Bioavailability Study of Ropinirole Implants in Parkinsons Patients on L-Dopa Switched From Oral Ropinirole; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT03250117
4. Phase 3 – A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC; 20201104; 20220713; https://ClinicalTrials.gov/show/NCT02489318
5. Phase 2 – Immunological and Regenerative Implications of Corrosion of Dental Materials in Children and Adolescents; 20181231; 20191230; https://ClinicalTrials.gov/show/NCT033344614) BVSN – BroadVision, Inc.
a. Buy at < ~ $2.30
b. Sell at >~ $3.15What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/09/2018 – 04/13/2018, and Why?
April 22, 2018 at 9:04 am #3275KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/23/2018 – 04/27/2018:
1) TIK – Tel-Instrument Electronics Corp.
a. Buy at < ~ $2.06
b. Sell at >~ $3.852) BVSN – BroadVision, Inc.
a. Buy at <~ $2.30
b. Sell at >~ $3.153) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.30
b. Sell at >~ $1.99What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/23/2018 – 04/27/2018, and Why?
April 22, 2018 at 9:37 am #3279KeymasterBullish Stocks currently Trading Below Cash (TBC) as of 04/20/2018 include:
- $BVSN – BroadVision, Inc. :
- Cash/sh = $2.26
- $CLDX – Celldex Therapeutics, Inc. :
- Cash/sh = $0.95
- $DCAR – DropCar, Inc. :
- Cash/sh = $1.92
- $EGLT – Egalet Corporation :
- Cash/sh = $2.31
- $FCSC – Fibrocell Science, Inc. :
- Cash/sh = $0.77
- $OPHT – Ophthotech Corporation :
- Cash/sh = $4.63
- $OVAS – OvaScience, Inc. :
- Cash/sh = $1.88
- $VICL – Vical Incorporated :
- Cash/sh = $2.67
- $VVUS – VIVUS, Inc. :
- Cash/sh = $2.14
Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?
April 22, 2018 at 9:57 am #3280Keymaster#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 04/20/2018 include:
- $CECE – CECO Environmental Corp. :
- Book/sh = $5.17
- $CLDX – Celldex Therapeutics, Inc. :
- Book/sh = $1.73
- $DCAR – DropCar, Inc. :
- Book/sh = $3.01
- $KOOL – Cesca Therapeutics Inc. :
- Book/sh = $3.36
- $OVAS – OvaScience, Inc. :
- Book/sh = $1.80
- $ROSG – Rosetta Genomics Ltd. :
- Book/sh = $0.43
- $VICL – Vical Incorporated :
- Book/sh = $3.29
Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?
April 29, 2018 at 8:26 am #3301KeymasterThe following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/30/2018 – 05/04/2018:
1) TIK – Tel-Instrument Electronics Corp.
a. Buy at < ~ $2.05
b. Sell at >~ $3.852) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.453) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99What do you think about these Stock Picks to Buy at these Price Targets?
What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/30/2018 - 05/04/2018, and Why?
- $AVIR – Aviragen Therapeutics Inc :
-
AuthorPosts
- You must be logged in to reply to this topic.
